For Health Care Professionals Outside the US



Abdi J, Chen G, Chang H. Drug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms. Oncotarget. 2013;4(12):2186-2207.

Atadja P. Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges. Cancer Lett. 2009;280(2):233-241.

Atadja PW. HDAC inhibitors and cancer therapy. Prog Drug Res. 2011:67;175-195.

Bazzi M, Badros A. Multiple myeloma: implementing signaling pathways and molecular biology in clinical trials. Cancer Biol Ther. 2010;10(9):830-838.

Catley L, Weisberg E, Kiziltepe T, et al. Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells. Blood. 2006;108(10):3441-3449.

Cea M, Cagnetta A, Gobbi M, et al. New insights into the treatment of multiple myeloma with histone deacetylase inhibitors. Curr Pharm Des. 2013;19(4):734-744.

Data on file. FARYDAK (panobinostat) core data sheet version 1.0. Novartis Pharmaceuticals Corp; May 2014.

Data on file. Clinical study report CLBH589D2308. Novartis Pharmaceuticals Corp; Feb 2014.

De Bruyne E, Bos TJ, Schuit F, et al. IGF-1 suppresses Bim expression in multiple myeloma via epigenetic and posttranslational mechanisms. Blood. 2010;115(12):2430-2440.

Dimopoulos MA, San-Miguel JF, Anderson KC. Emerging therapies for the treatment of relapsed or refractory multiple myeloma. Eur J Haematol. 2011; 86(1):1-15.

Dimopoulos K, Gimsing P, Grønbæk K. The role of epigenetics in the biology of multiple myeloma. Blood Cancer J. 2014;4:e207.

Dimopoulos MA, Richardson PG, Moreau P, et al. Current treatment landscape for relapsed and/or refractory multiple myeloma. Nat Rev Clin Oncol. 2015;12(1):42-54.

FARYDAK® (panobinostat). EU Summary of Product Characteristics. Secura Bio Limited; November 2019.

Kröger N. The European Group for Blood and Marrow Transplantation: multiple myeloma. Accessed July 22, 2015.

Mithraprabhu S, Kalff A, Chow A, et al. Dysregulated class I histone deacetylases are indicators of poor prognosis in multiple myeloma. Epigenetics. 2014;9(11):1511-1520.

Ocio EM, Vilanova D, Atadja P, et al. In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma. Haematologica. 2010;95(5):794-803.

Rajkumar SV, Fonseca R, Dewald GW, et al. Cytogenetic abnormalities correlate with the plasma cell labeling index and extent of bone marrow involvement in myeloma. Cancer Genet Cytogenet. 1999;113(1):73-77.

Revlimid® (lenalidomide). EU Summary of Product Characteristics. Celegene Pharmaceuticals; June 2012.

San-Miguel JF, Hungria VT, Yoon SS, et al. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. Lancet Oncol. 2014;15(11):1195-1206.

San-Miguel J, Hungria VTM, Yoon S, et al. Panobinostat plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma who received prior bortezomib and IMiDs: a predefined subgroup analysis of PANORAMA 1. Presented at: ASCO 2015; May 29-June 2, 2015; Chicago, IL.

San-Miguel J, Hungria VTM, Yoon S, et al. Efficacy and safety based on duration of treatment of panobinostat plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma in the phase 3 Panorama 1 study. Presented at: 56th ASH Annual Meeting and Exposition; December 6-9, 2014; San Francisco, CA.

Velcade® (bortezomib). EU Summary of Product Characteristics. Janssen Pharmaceuticals; September 2012.

Zhu YX, Kortuem KM, and Stewart AK. Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide, and pomalidomide in multiple myeloma. Leuk Lymphoma. 2013;54(4):683-687.